QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 100.18
-- x --
-- x --
-- - --
$ 71.06 - $ 100.28
17,216
na
0
$ 0.86
nm
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Reuters

Core News & Articles

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results...

Core News & Articles

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issu...

 fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced...

 arcturus-therapeutics-lung-disease-candidate-triggers-bullish-rating-analyst-sees-over-200-upside

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine...

 credit-suisses-17b-of-at1-debt-written-down-to-zero-richard-bransons-virgin-orbit-plans-insolvency-court-freezes-volkswagens-russian-assets-todays-top-stories

Reuters

 the-daily-biotech-pulse-fda-orphan-drug-tags-for-neurocrine-editas-candidates-sale-of-bridgebios-prv-rmat-designation-for-polaritytes-product

Here's a roundup of top developments in the biotech space over the last 24 hours:

 csl-seals-117b-buyout-deal-of-vifor-pharma-probably-the-largest-healthcare-deal-in-2021

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed&nb

Core News & Articles

The National Institutes of Health (NIH) has halted a trial evaluating the safety and effectiveness<

Core News & Articles

CSL (OTC: CSLLY) confirmed it will commence manufacturing the University of Oxford/AstraZeneca (NYSE: AZN) AZD1222 COVID-19 vac...